卡格列净对2型糖尿病合并慢性肾病患者心血管及肾脏结局的影响:一级与二级预防亚组分析
CREDENCE试验纳入4401例2型糖尿病合并慢性肾病患者,随机接受卡格列净或安慰剂。卡格列净总体降低主要心血管事件风险(HR 0.80,95%CI 0.67-0.95,P=0.01),一级预防组(HR 0.68,95%CI 0.49-0.94)与二级预防组(HR 0.85,95%CI 0.69-1.06)效应一致(交互P=0.25)。肾脏复合终点及心血管死亡或心衰住院复合终点在两组中均一致降低(交互P均>0.5)。
要点
- 卡格列净降低2型糖尿病合并慢性肾病患者主要心血管事件风险。
- 无心血管病史的一级预防患者同样获益,心血管事件HR 0.68。
- 肾脏复合终点及心衰住院复合终点在一、二级预防组均一致降低。
核心结论
- 卡格列净显著降低2型糖尿病合并慢性肾病患者的主要心血管事件和肾衰竭风险,包括无既往心血管疾病的一级预防患者。
研究设计与样本
- CREDENCE试验为随机对照试验,纳入4401例2型糖尿病合并慢性肾病患者,随机接受卡格列净或安慰剂,背景为优化标准治疗。
- 一级预防组2181例(49.6%),二级预防组2220例(50.4%)。
主要发现
- 卡格列净总体降低主要心血管事件风险(HR 0.80,95%CI 0.67-0.95;P=0.01)。
- 一级预防组主要心血管事件HR 0.68(95%CI 0.49-0.94),二级预防组HR 0.85(95%CI 0.69-1.06),交互P=0.25。
- 心血管死亡HR 0.78(95%CI 0.61-1.00),非致死性心肌梗死HR 0.81(95%CI 0.59-1.10),非致死性卒中HR 0.80(95%CI 0.56-1.15)。
- 肾脏主要复合终点及心血管死亡或心衰住院复合终点在一、二级预防组均一致降低(交互P均>0.5)。
临床怎么用
- 对于2型糖尿病合并慢性肾病患者,无论有无既往心血管疾病,均可考虑使用卡格列净以降低心血管事件和肾脏终点风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Canagliflozin reduces the risk of kidney failure in patients with type 2 diabetes mellitus and chronic kidney disease, but effects on specific cardiovascular outcomes are uncertain, as are effects in people without previous cardiovascular disease (primary prevention). METHODS: In CREDENCE (Canagliflozin and Renal Events in Diabetes With Established Nephropathy Clinical Evaluation), 4401 participants with type 2 diabetes mellitus and chronic kidney disease were randomly assigned to canagliflozin or placebo on a background of optimized standard of care. RESULTS: Primary prevention participants (n=2181, 49.6%) were younger (61 versus 65 years), were more often female (37% versus 31%), and had shorter duration of diabetes mellitus (15 years versus 16 years) compared with secondary prevention participants (n=2220, 50.4%). Canagliflozin reduced the risk of major cardiovascular events overall (hazard ratio [HR], 0.80 [95% CI, 0.67-0.95]; P=0.01), with consistent reductions in both the primary (HR, 0.68 [95% CI, 0.49-0.94]) and secondary (HR, 0.85 [95% CI, 0.69-1.06]) prevention groups (P for interaction=0.25). Effects were also similar for the components of the composite including cardiovascular death (HR, 0.78 [95% CI, 0.61-1.00]), nonfatal myocardial infarction (HR, 0.81 [95% CI, 0.59-1.10]), and nonfatal stroke (HR, 0.80 [95% CI, 0.56-1.15]). The risk of the primary composite renal outcome and the composite of cardiovascular death or hospitalization for heart failure were also consistently reduced in both the primary and secondary prevention groups (P for interaction >0.5 for each outcome). CONCLUSIONS: Canagliflozin significantly reduced major cardiovascular events and kidney failure in patients with type 2 diabetes mellitus and chronic kidney disease, including in participants who did not have previous cardiovascular disease. CLINICAL TRIAL REGISTRATION: URL: https://www.clinicaltrials.gov. Unique identifier: NCT02065791.
引用
- Mahaffey KW, Jardine MJ, Bompoint S, et al. Canagliflozin and Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus and Chronic Kidney Disease in Primary and Secondary Cardiovascular Prevention Groups. Circulation. 2019. PMID: 31291786. doi:10.1161/CIRCULATIONAHA.119.042007
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。